These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 18657182)

  • 1. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.
    Loría F; Petrosino S; Mestre L; Spagnolo A; Correa F; Hernangómez M; Guaza C; Di Marzo V; Docagne F
    Eur J Neurosci; 2008 Aug; 28(4):633-41. PubMed ID: 18657182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis.
    Loría F; Petrosino S; Hernangómez M; Mestre L; Spagnolo A; Correa F; Di Marzo V; Docagne F; Guaza C
    Neurobiol Dis; 2010 Jan; 37(1):166-76. PubMed ID: 19815071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurobiology and evolution of cannabinoid signalling.
    Elphick MR; Egertová M
    Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of cannabinoid receptor ligands: current status.
    Singh J; Budhiraja S
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis.
    Ortega-Gutiérrez S; Molina-Holgado E; Arévalo-Martín A; Correa F; Viso A; López-Rodríguez ML; Di Marzo V; Guaza C
    FASEB J; 2005 Aug; 19(10):1338-40. PubMed ID: 15941768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain.
    Jhaveri MD; Richardson D; Robinson I; Garle MJ; Patel A; Sun Y; Sagar DR; Bennett AJ; Alexander SP; Kendall DA; Barrett DA; Chapman V
    Neuropharmacology; 2008 Jul; 55(1):85-93. PubMed ID: 18534634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacology of cannabinoid receptors and their ligands: an overview.
    Pertwee RG
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.
    Docagne F; Muñetón V; Clemente D; Ali C; Loría F; Correa F; Hernangómez M; Mestre L; Vivien D; Guaza C
    Mol Cell Neurosci; 2007 Apr; 34(4):551-61. PubMed ID: 17229577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From endocannabinoid profiling to 'endocannabinoid therapeutics'.
    Ligresti A; Petrosino S; Di Marzo V
    Curr Opin Chem Biol; 2009 Jun; 13(3):321-31. PubMed ID: 19497779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
    McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
    Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.
    Manterola A; Bernal-Chico A; Cipriani R; Canedo-Antelo M; Moreno-García Á; Martín-Fontecha M; Pérez-Cerdá F; Sánchez-Gómez MV; Ortega-Gutiérrez S; Brown JM; Hsu KL; Cravatt B; Matute C; Mato S
    Biochem Pharmacol; 2018 Nov; 157():189-201. PubMed ID: 30075103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
    Sain NM; Liang A; Kane SA; Urban MO
    Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
    Petrosino S; Di Marzo V
    Curr Opin Investig Drugs; 2010 Jan; 11(1):51-62. PubMed ID: 20047159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid signalling in the enteric nervous system.
    Galligan JJ
    Neurogastroenterol Motil; 2009 Sep; 21(9):899-902. PubMed ID: 19689654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid receptors and their ligands.
    Pertwee RG; Ross RA
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):101-21. PubMed ID: 12052030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endocannabinoid system and gut-brain signalling.
    Storr MA; Sharkey KA
    Curr Opin Pharmacol; 2007 Dec; 7(6):575-82. PubMed ID: 17904903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids for the treatment of inflammation.
    Ashton JC
    Curr Opin Investig Drugs; 2007 May; 8(5):373-84. PubMed ID: 17520866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases.
    Moreno-Martet M; Mestre L; Loría F; Guaza C; Fernández-Ruiz J; de Lago E
    Neurosci Lett; 2012 Feb; 508(2):67-72. PubMed ID: 22206832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut feelings about the endocannabinoid system.
    Di Marzo V; Piscitelli F
    Neurogastroenterol Motil; 2011 May; 23(5):391-8. PubMed ID: 21481098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid system and neuroinflammation: implications for multiple sclerosis.
    Correa F; Docagne F; Mestre L; Loría F; Hernangómez M; Borrell J; Guaza C
    Neuroimmunomodulation; 2007; 14(3-4):182-7. PubMed ID: 18073512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.